MorphoSys Non Currrent Assets Other vs Common Stock Total Equity Analysis
MOR Stock | USD 18.42 0.01 0.05% |
MorphoSys financial indicator trend analysis is infinitely more than just investigating MorphoSys AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MorphoSys AG ADR is a good investment. Please check the relationship between MorphoSys Non Currrent Assets Other and its Common Stock Total Equity accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Non Currrent Assets Other vs Common Stock Total Equity
Non Currrent Assets Other vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MorphoSys AG ADR Non Currrent Assets Other account and Common Stock Total Equity. At this time, the significance of the direction appears to have very week relationship.
The correlation between MorphoSys' Non Currrent Assets Other and Common Stock Total Equity is 0.2. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of MorphoSys AG ADR, assuming nothing else is changed. The correlation between historical values of MorphoSys' Non Currrent Assets Other and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of MorphoSys AG ADR are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Non Currrent Assets Other i.e., MorphoSys' Non Currrent Assets Other and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.2 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from MorphoSys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MorphoSys AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. At this time, MorphoSys' Selling General Administrative is relatively stable compared to the past year. As of 06/14/2024, Sales General And Administrative To Revenue is likely to grow to 0.38, though Tax Provision is likely to grow to (1.1 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 181.5M | 116.5M | 109.9M | 115.4M | Depreciation And Amortization | 98.4M | 10.5M | 10.5M | 10.4M |
MorphoSys fundamental ratios Correlations
Click cells to compare fundamentals
MorphoSys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MorphoSys fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 496.4M | 1.7B | 2.6B | 2.4B | 2.0B | 2.1B | |
Other Current Liab | 46.8M | 146.9M | 206.9M | 230.2M | 202.4M | 212.5M | |
Total Current Liabilities | 61.6M | 200.5M | 284.5M | 278.3M | 264.3M | 277.5M | |
Total Stockholder Equity | 394.7M | 621.3M | 244.9M | 157.4M | 49.0M | 46.6M | |
Property Plant And Equipment Net | 4.7M | 50.7M | 49.6M | 51.0M | 15.0M | 11.8M | |
Net Debt | (1.7M) | 208.4M | 202.5M | (62.9M) | 477.4M | 501.3M | |
Retained Earnings | (255.8M) | (157.9M) | (672.3M) | (823.4M) | (1.0B) | (962.5M) | |
Accounts Payable | 10.7M | 47.6M | 73.8M | 38.6M | 28.4M | 14.7M | |
Cash | 44.3M | 109.8M | 123.2M | 402.4M | 158.5M | 166.4M | |
Non Current Assets Total | 192.7M | 452.7M | 1.4B | 1.3B | 1.2B | 1.3B | |
Non Currrent Assets Other | 44.1M | 1.6M | 4.1M | 8.7M | 1.2M | 1.2M | |
Cash And Short Term Investments | 272.5M | 1.1B | 993.7M | 907.2M | 682.8M | 716.9M | |
Common Stock Total Equity | 29.4M | 31.8M | 32.0M | 32.9M | 37.8M | 34.8M | |
Common Stock Shares Outstanding | 126.4M | 132.7M | 133.6M | 136.6M | 137.3M | 108.5M | |
Liabilities And Stockholders Equity | 496.4M | 1.7B | 2.6B | 2.4B | 2.0B | 2.1B | |
Non Current Liabilities Total | 40.2M | 837.7M | 2.0B | 2.0B | 1.7B | 1.8B | |
Other Current Assets | (40.3K) | 10.0M | 15.9M | (367.0) | 24.0 | 22.8 | |
Other Stockholder Equity | 619.8M | 744.1M | 830.2M | 831.3M | 936.1M | 982.9M | |
Total Liab | 101.7M | 1.0B | 2.3B | 2.2B | 2.0B | 2.1B | |
Property Plant And Equipment Gross | 20.8M | 50.7M | 69.9M | 71.5M | 37.7M | 39.6M | |
Total Current Assets | 303.7M | 1.2B | 1.1B | 1.1B | 814.0M | 854.7M | |
Intangible Assets | 41.1M | 69.4M | 838.3M | 886.6M | 844.1M | 886.3M | |
Common Stock | 31.8M | 32.0M | 32.9M | 34.2M | 37.7M | 35.4M | |
Other Assets | 1.1M | 134.4M | 199.8M | 8.7M | 10.0M | 9.5M | |
Net Receivables | 20.3M | 89.8M | 85.8M | 112.4M | 42.7M | 83.8M | |
Inventory | 288.2K | 10.0M | 20.8M | 24.3M | 62.1M | 65.2M | |
Short Long Term Debt Total | 42.6M | 318.2M | 325.8M | 339.5M | 635.9M | 667.7M | |
Good Will | 3.7M | 1.6M | 335.6M | 356.2M | 342.3M | 359.4M | |
Accumulated Other Comprehensive Income | (1.3M) | 2.2M | 52.8M | 115.3M | 88.4M | 92.9M | |
Current Deferred Revenue | 1.6M | 2.5M | 223.9K | 19.4M | 17.5M | 18.4M | |
Short Term Investments | 228.2M | 980.5M | 870.4M | 504.8M | 524.3M | 372.9M | |
Short Term Debt | 2.5M | 3.5M | 3.7M | 9.6M | 14.1M | 14.2M | |
Other Liab | 138.1K | 523.0M | 1.7B | 1.6B | 1.9B | 2.0B | |
Net Tangible Assets | 349.9M | 550.3M | (929.0M) | (1.1B) | (976.9M) | (928.0M) | |
Long Term Debt | 0.0 | 272.8M | 282.8M | 291.6M | 613.1M | 643.7M | |
Long Term Investments | 96.0M | 99.0M | 196.6M | 5.4M | 3.6M | 3.4M | |
Property Plant Equipment | 47.8M | 50.7M | 49.6M | 51.0M | 58.6M | 61.6M | |
Capital Lease Obligations | 42.6M | 45.0M | 42.6M | 45.8M | 12.4M | 23.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for MorphoSys Stock Analysis
When running MorphoSys' price analysis, check to measure MorphoSys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MorphoSys is operating at the current time. Most of MorphoSys' value examination focuses on studying past and present price action to predict the probability of MorphoSys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MorphoSys' price. Additionally, you may evaluate how the addition of MorphoSys to your portfolios can decrease your overall portfolio volatility.